Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 7

1.

SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells.

Zhi H, Yang XJ, Kuhnmuench J, Berg T, Thill R, Yang H, See WA, Becker CG, Williams CL, Li R.

J Pathol. 2009 Feb;217(3):389-97. doi: 10.1002/path.2456.

PMID:
18973191
2.

The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A.

World J Urol. 2007 Oct;25(5):477-89. Epub 2007 May 31. Review.

PMID:
17541600
3.

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.

Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Cassinello Espinosa J, Antón Aparicio LM.

Clin Transl Oncol. 2007 Nov;9(11):694-702. Review.

PMID:
18055324
4.

Differential role of TRP channels in prostate cancer.

Prevarskaya N, Flourakis M, Bidaux G, Thebault S, Skryma R.

Biochem Soc Trans. 2007 Feb;35(Pt 1):133-5. Review.

PMID:
17233619
5.

Genetic and microenvironmental implications in prostate cancer progression and metastasis.

Alberti C.

Eur Rev Med Pharmacol Sci. 2008 May-Jun;12(3):167-75. Review.

PMID:
18700688
6.

The role of inflammation and infection in the pathogenesis of prostate carcinoma.

Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W.

BJU Int. 2007 Oct;100(4):733-7. Epub 2007 Jul 23. Review.

7.

[Rare malignant tumours of the prostate].

Mazerolles C, Chevreau C.

Bull Cancer. 2007 Jul;94(7 Suppl):F44-9. Review. French.

PMID:
17845993
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk